RCKT Insider Trading

Insider Ownership Percentage: 28.50%
Insider Buying (Last 12 Months): $200,765.30
Insider Selling (Last 12 Months): $588,757.00

Rocket Pharmaceuticals Insider Trading History Chart

This chart shows the insider buying and selling history at Rocket Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$201kbought$45ksoldQ2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2-$10M$0$10MTotal Insider BuyingTotal Insider Selling

Rocket Pharmaceuticals Share Price & Price History

Current Price: $6.72
Price Change: Price Increase of +0.67 (11.07%)
As of 05/15/2025 05:00 PM ET

This chart shows the closing price history over time for RCKT up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
JunJulAugSepOctNovDecJanFebMarAprMay$6.05Closing price on 05/14/25:

SEC Filings (Institutional Ownership Changes) for Rocket Pharmaceuticals (NASDAQ:RCKT)

98.39% of Rocket Pharmaceuticals stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at RCKT by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table
2022202320242025$15Mbought$15MsoldQ2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2-$100M-$50M$0$50M$100MTotal InflowsTotal Outflows
Rocket Pharmaceuticals logo
Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia. The company also has a clinical stage in vivo adeno-associated virus program for Danon disease, a multi-organ lysosomal-associated disorder leading to early death due to heart failure; Plakophilin-2 Arrhythmogenic Cardiomyopathy, an inheritable cardiac disorder; and BAG3 Dilated Cardiomyopathy. It has license agreements with Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, Centro de Investigacion Biomedica En Red, and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz; UCL Business PLC; The Regents of the University of California; and REGENXBIO, Inc. Rocket Pharmaceuticals, Inc. was founded in 1999 and is headquartered in Cranbury, New Jersey.
Read More on Rocket Pharmaceuticals

Today's Range

Now: $6.72
Low: $5.72
High: $7.14

50 Day Range

MA: $7.00
Low: $4.79
High: $8.83

52 Week Range

Now: $6.72
Low: $4.55
High: $26.98

Volume

6,491,548 shs

Average Volume

1,467,726 shs

Market Capitalization

$717.60 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.02

Who are the company insiders with the largest holdings of Rocket Pharmaceuticals?

Rocket Pharmaceuticals' top insider investors include:
  1. Gotham Makker (Director)
  2. Gaurav Shah (CEO)
  3. Kinnari Patel (Insider)
  4. Aaron Ondrey (CFO)
  5. David P Southwell (Director)
  6. Mark Andrew White (Insider)
  7. Martin Wilson (General Counsel)
  8. John Militello (Insider)
Learn More about top insider investors at Rocket Pharmaceuticals.

Who are the major institutional investors of Rocket Pharmaceuticals?

Rocket Pharmaceuticals' top institutional shareholders include:
  1. Wellington Management Group LLP — 11.82%
  2. Vanguard Group Inc. — 6.20%
  3. Westfield Capital Management Co. LP — 4.51%
  4. Comerica Bank — 0.76%
  5. Charles Schwab Investment Management Inc. — 0.63%
  6. Siren L.L.C. — 0.55%
Learn More about top institutional investors of Rocket Pharmaceuticals stock.

Which major investors are selling Rocket Pharmaceuticals stock?

Within the last quarter, RCKT stock was sold by these institutional investors:
  1. Wellington Management Group LLP
  2. Russell Investments Group Ltd.
  3. Tema Etfs LLC
  4. XTX Topco Ltd
  5. TD Asset Management Inc
  6. Siren L.L.C.
  7. Torray Investment Partners LLC
  8. Blair William & Co. IL
During the previous year, company insiders that have sold Rocket Pharmaceuticals company stock include:
  1. Gotham Makker (Director)
  2. Gaurav Shah (CEO)
  3. Kinnari Patel (Insider)
  4. Aaron Ondrey (CFO)
  5. David P Southwell (Director)
Learn More investors selling Rocket Pharmaceuticals stock.

Which major investors are buying Rocket Pharmaceuticals stock?

In the previous quarter, RCKT stock was acquired by institutional investors including:
  1. Federated Hermes Inc.
  2. Jump Financial LLC
  3. Nuveen LLC
  4. Sovran Advisors LLC
  5. Mirador Capital Partners LP
  6. Synovus Financial Corp
  7. Westfield Capital Management Co. LP
  8. AlphaQuest LLC
During the previous year, these company insiders have bought Rocket Pharmaceuticals stock:
  1. Gotham Makker (Director)
  2. Gaurav Shah (CEO)
Learn More investors buying Rocket Pharmaceuticals stock.